Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.
The House Ways & Means Committee on May 21 unanimously advanced the Provider Reimbursement Stability Act of 2026, which is endorsed by multiple radiology societies.
The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June.
"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
